Recent Updates
Recently added Catalysts

Upcoming Catalyst

Drug Pipeline Intelligence

Clinical Trial Results

Inside Trades

Options Data

News Section

Hedge Funds

Ownership Trends

Competitive Position

Cocrystal Pharma, Inc.

35 indications, side-by-side phase, drug & LoA

$0.99

-0.02 (-1.5%)

D 31Pipeline Score Overvalued Pharma · Clinical
Market Cap
15.86 M
EPS
-0.73
P/E Ratio
-
Value Trade
79.28 K
SEC Financials
Q1 2026

  • Dilution Risk

    80%

  • Revenue

    225.00 K

  • R&D Expenses

    1.37 M

  • Operating CF

    -2.34 M

  • Total Assets

    7.43 M

  • Total Liabilities

    3.31 M

  • Equity

    4.12 M

  • D/E Ratio

    12,345

-6.5 %
Week
-19.01 %
1 Month
16.76 %
3 Month
26.37 %
6 Month
-91.52 %
5 Year
-95.74 %
All Time
Cash Data
Distressed

  • Cash Position

    4.68 M

  • Monthly Burn

    780.00 K

  • Runway

    5.1 mo

  • Burn Trend

    Stable

  • SEC Filing

    May 15, 2026
Overview
Volume
80.61 K
52 Week Range
0.86 - 2.67
% held by Insiders
34.28 %
% held by Institutions
5.63 %
Enterprise Value
12.52 M
Total Shares
13.79 M
Short %
1.39 %
Float Shares
10.27 M
Company Description
HQ: 19805 N. CREEK PARKWAY, BOTHEL...
Employees:10
https://www.cocrystalpharma.co...

locked

Upcoming Catalyst
Catalyst Drug/Treatment Stage Probability of Approval Description Drug Type Therapeutic Area Source
PDUFA 2026
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Example Drug Treatment for example condition requiring FDA review
Phase 3
-%
Small Molecule
Oncology
Unlock Upcoming Catalyst data
Drug Pipeline Intelligence
D31
Pipeline Score
$8M
Pipeline Value
Overvalued
Valuation Signal
3
Drugs Scored
0.5x
rNPV / MCap
Top 39%
Micro Cap
(rank 553 of 905)
Percentile Rank
Cocrystal Pharma, Inc. faces pipeline headwinds (31/100), with $1.2B risk-adjusted pipeline value, led by CDI-31244 in Chronic Hepatitis C (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
DrugIndicationPhaseNCT IDPTRSrNPVStatusEnrollmentVelocityDesignCompletionML SignalLast Change
CDI-31244
Small molecule		Chronic Hepatitis CPhase 2NCT0350155021% $651M COMPLETED 12 - -Jun 7, 2019 -Apr 28, 2021
Unlock Drug Pipeline Intelligence
Clinical Trial Results
Drug Name Indications Phase Date Trial Results Summary Title Source
CDI-988
Norovirus
Phase 1
2025-08-06
CDI-988
Norovirus
Phase 1
2025-08-06
CDI-988
Norovirus
Phase 1
2025-08-06
Unlock Clinical Trial Results data
Inside Trades
TREND
CORPORATE INSIDERS BOUGHT SHARES WORTH 1.8M IN THE LAST 3 MONTHS
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Unlock Inside Trades data
Show Data
Hedge Funds
TREND
HEDGE FUNDS INCREASED HOLDINGS BY 200.0K SHARES IN THE LAST QUARTER
Shares Held
2040.00B1530.00B1020.00B510.00B0
Q3
2024
Q4
2024
Q1
2025
Q2
2025
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Fund Count
60%
Share Volume
25%
Conviction
15%
Hedge Funds invested in COCP
HedgeFund Name
( 3 )
% of Portfolio Current MV
-
Shares Owned
-
Activity
Avg Price $0

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K

Example Capital Management

2.5 %
15.00 M
250.00 K
Unlock Hedge Funds table data
Biotech Analyst Ratings
Symbol
Firm
Rating
Action
Price Target
Upside
date
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
COCP
Example Securities
Buy
Initiated
$150.00
+25%
2026-01-15
Unlock Biotech Analyst Ratings data
COCP Stock Forecast & Analyst Consensus
BUY
Analyst Ratings
Buy65.0%
Hold25.0%
Sell10.0%
Price Target Trend
Average$24.00
Low$18.00
High$32.00
Unlock Price Target Trend
COCP Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
ExpirationVolumeOpen InterestImplied Volatility CallsImplied Volatility Puts
CallsPutsPut-Call RatioCallsPutsPut-Call RatioIVOiWaIvVWaIvIVOiWaIvVWaIv
Unlock Option Chain Statistics data
Option Chain
CallsStrikePuts
Last PriceVolumeOpen InterestLast PriceVolumeOpen Interest
No data available
Unlock Option Chain data
Unlock Options Chart data
Open interest
0 600K 1.2M 1.8M Avg OI 1.00 M Open Interest
0 1 2 3 1.1 Put-Call Ratio
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
0 450K 900K 1.4M Avg OV 750.00 K Option Volume
0 1 2 3 0.95 Put-Call Ratio
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Latest Cocrystal Pharma, Inc. (COCP) News & Alerts
-
Sunday, June 14, 2026
(%)
+ More

Demo Biotech Announces Positive Phase 3 Results

Competitive Position
How COCP ranks across every disease it competes in
Indication Rank Phase Best DrugTop 3 Competitors Market $B LoA Position
Viral Infections #6 of 11 PHASE 1 CDI-988
GSK SVA VALN
—0.99 FOLLOWER